secwatch.observer — SEC 8-K summary
======================================

Issuer:     Veradermics, Inc (MANE)
CIK:        0001827635
Form:       8-K
Filed at:   2026-07-15T12:54:36+00:00
Accession:  0001827635-26-000023
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veradermics: Phase 2 VDPHL01 shows 22.7-23.3 hairs/cm² increase, 88.9-90% improved at Month 6
--------------------------------------------------------------------------------

- Mean non-vellus hair count increase of 22.7 hairs/cm² (once daily) and 23.3 hairs/cm² (twice daily) at Month 6.
- 88.9% (once daily) and 90.0% (twice daily) of patients reported 'improved' or 'much improved' on AAIRS at Month 6.
- Fast onset: 67.2% of participants graded by investigators as improved at Month 2, earliest measured time point.
- No treatment-related SAEs or cardiac AESIs; common AEs were hypertrichosis and peripheral edema.
- Topline results from Phase 2/3 Study '306' in female pattern hair loss expected in 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/0001827635-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1827635/000182763526000023/mane-20260715.htm
  HTML page:      https://secwatch.observer/filing/0001827635-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer